Date prepared: May 17, 2023
Abbreviated name of the issuer: CELON PHARMA S.A.
Subject: The Management Board’s and the Supervisory Board's recommendation on the coverage of loss for the year 2022 and payment of the dividend
Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.
Content of the report:
The Management Board of Celon Pharma S.A. (the “Company") informs that on May 17, 2023 it adopted a resolution on a recommendation for the Ordinary General Meeting of the Company on the coverage of the loss for the year 2022 and payment of the dividend. The Management Board's resolution received a positive opinion from the Supervisory Board on the same day.
The Management Board' indicated in its resolution that in relation to the occurrence of the Company’s net loss for the financial year 2022 in the amount of in PLN 39,277 thousand, the Management Board recommends that the aforementioned loss be covered by the part of the Company’s supplementary capital created from the share premium.
At the same time, the Management Board recommends the Company to pay out the dividend in the amount of PLN 0.09 (nine groszy) per one share, i.e. PLN 4,593,150.00 in total for all shares in the Company, whereas the amount of the recommended dividend will be paid out from the part of the Company's supplementary capital which was created from the profit generated in the previous years and complies with the requirements of Article 348 of the Commercial Companies Code.
The Management Board recommends June 30, 2023 as the dividend record date, and recommends that the dividend be paid out on July 6, 2023.
The final decision on coverage of the loss for the financial year 2022 and on payment of the dividend will be made by the Ordinary General Meeting of the Company.